Reuters: Health
Acasti Pharma Inc said on Monday its krill oil-derived drug candidate, CaPre, failed to show a statistically significant reduction in a type of fat found in blood compared to placebo in a late-stage study, sending its shares down 54%.
No comments:
Post a Comment